Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

BACKGROUND/AIMS: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare...

Full description

Saved in:
Bibliographic Details
Published in:Gut Liver
Main Authors: Lee, Yong Il, Park, Yehyun, Park, Soo Jung, Kim, Tae Il, Kim, Won Ho, Cheon, Jae Hee
Format: Artigo
Language:Inglês
Published: Editorial Office of Gut and Liver 2021
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960969/
https://ncbi.nlm.nih.gov/pubmed/32616683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl19433
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items